HPWM
TEVA icon

High Point Wealth Management’s Teva Pharmaceutical Industries Limited TEVA Stock Holding History

High Point Wealth Management’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.57K Hold
135
– – ﹤0.01% 233
2026
Q1 		$4.07K Hold
135
– – ﹤0.01% 235
2025
Q4 		$4.21K Buy
+135
New +$3.33K ﹤0.01% 227

Other funds holding TEVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return
WCM Investment Management
WCM Investment Management Laguna Beach, California $55.2B AUM 57.07% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return

High Point Wealth Management's TEVA Position: Q2 2026 in Review

High Point Wealth Management held its Teva Pharmaceutical Industries Limited (TEVA) position steady in Q2 2026 at 135 shares worth $4.57K. The position accounts for ﹤0.01% of the portfolio, ranked #233.

High Point Wealth Management first reported a position in TEVA in Q4 2025 and has held it in 3 quarters since. 676 funds tracked by Wall St. Rank hold TEVA as of Q2 2026.

  • High Point Wealth Management held 135 shares of Teva Pharmaceutical Industries Limited worth $4.57K as of Q2 2026.
  • High Point Wealth Management left its Teva Pharmaceutical Industries Limited share count unchanged in Q2 2026.
  • Teva Pharmaceutical Industries Limited made up ﹤0.01% of High Point Wealth Management's portfolio in Q2 2026, its #233 holding.
  • High Point Wealth Management first reported a position in Teva Pharmaceutical Industries Limited in Q4 2025 and has held it in 3 quarters since.
  • 676 funds tracked by Wall St. Rank held Teva Pharmaceutical Industries Limited as of Q2 2026.

Based on High Point Wealth Management's 13F filing for Q2 2026, filed 20 Jul 2026.